// App-Quantinova.ai

4560 : Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (LEN) + pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms.

Researchers

Presenter

  • Viktor Grnwald

Principal Investigators

  • Evgeny Kopyltsov

  • Vadim Kozlov

  • Teresa Alonso Gordoa

  • Masatoshi Eto

  • Thomas E. Hutson

  • Robert J. Motzer

  • Eric Winquist

  • Pablo Maroto-Rey

  • Bhumsuk Keam

  • Giuseppe Procopio

  • Shirley Wong

  • Bohuslav Melichar

  • Frederic Rolland

  • Mototsugu Oya

  • Karla Rodriguez-Lopez

  • Kenichi Saito

  • Alan D. Smith

  • Camillo Porta

Medical Centers

  • University Hospital of Essen, Essen, Germany

  • The Royal Free NHS Trust, London, United Kingdom

  • State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russian Federation

  • State Budgetary Health Care Institution “Novosibirsk Regional Clinical Oncology Dispensary”, Novosibirsk, Russian Federation

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • Kyushu University, Fukuoka, Japan

  • Texas Oncology, Dallas, TX

  • Memorial Sloan Kettering Cancer Center, New York, NY, Western University, London, ON, Canada

  • Hospital Santa Creu i Sant Pau, Barcelona, Spain

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Western Health, Vic, Australia

  • Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic, Centre René Gauducheau Centre de Lutte Contre Le Cancer Nantes, Saint-Herblain, France

  • Merck & Co., Inc., Kenilworth, NJ, Eisai Inc., Woodcliff Lake, NJ, Eisai Ltd., Hatfield, United Kingdom

  • IRCCS San Matteo University Hospital Foundation, Padua, Italy

Locations

  • Germany

  • United Kingdom

  • Russia

  • Spain

  • Japan

  • Canada

  • Italy

  • Australia

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Pembrolizumab

  • Everolimus

  • Lenvatinib

  • Sunitinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02811861

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved